Heptares Therapeutics, a subsidiary of Tokyo-based Sosei Group Corp., has been awarded a $5.5 million grant from the National Institute on Drug Abuse. Together with additional funding from Heptares, the grant will support a three-year research project aimed at developing a selective antagonist for the human orexin-1 receptor for use in treating cocaine addiction and dependence, for which there are currently no approved treatments.